# HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

> **NCT07459673** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer
- Breast Cancer Stage IV

## Interventions

- **DIAGNOSTIC_TEST:** Personalis NeXT Personal
- **DIAGNOSTIC_TEST:** Natera Signatera
- **BIOLOGICAL:** Trastuzumab deruxtecan-nxki

## Key facts

- **NCT ID:** NCT07459673
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2030-03-04
- **Final completion:** 2030-03-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07459673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07459673, "HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07459673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*